095700 — Genexine Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	27,536	-48,561	-57,132	-66,860	-63,706
Depreciation
Amortisation
Non-Cash Items	-62,256	33,990	30,851	17,808	49,903
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	9,109	-1,473	-18,328	6,029	6,783
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-22,691	-12,745	-39,800	-38,055	-1,648
Capital Expenditures	-24,116	-57,007	-31,779	-7,379	-7,303
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-40,278	49,302	29,864	-26,904	-3,914
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-64,394	-7,704	-1,915	-34,283	-11,217
Financing Cash Flow Items	—	6,471	—	-13,117	-339
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	73,358	43,087	31,632	60,427	7,961
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-13,881	22,584	-9,853	-11,910	-4,867